Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Psoriasis: Can Immune Modulation Help?
Transcript
- 0:00SPEAKER_00: Welcome to this Rona Cell Podcast.
- 0:02SPEAKER_00: What if I told you that um that red flaky skin on your elbow actually has absolutely nothing to do with your skin?
- 0:09SPEAKER_01: Yeah, that's uh that's a really common misconception we run into all the time.
- 0:12SPEAKER_00: Like, what if I told you that patch of angry skin is really just a symptom of a fire alarm going off deep inside your immune system?
- 0:19SPEAKER_00: Maybe it was triggered by, I don't know, a stressful presentation you gave at work three weeks ago.
- 0:24SPEAKER_01: Well, that is absolutely what we are getting into today.
- 0:27SPEAKER_01: We are doing a deep dive into the underlying mechanics of a condition that affects millions, but is, honestly, almost universally misunderstood.
- 0:36SPEAKER_00: And our guide today is a comprehensive look into clinical data from Saronacell, which is a regenerative medicine clinic based in Kuala Lumpur, Malaysia.
- 0:45SPEAKER_00: We're looking at a fascinating new perspective on the treatment of psoriasis, drawing directly from their research.
- 0:50SPEAKER_01: Aaron Powell But I want to set the baseline immediately for you, just so you're clear.
- 0:54SPEAKER_01: We're looking at a complex chronic condition here.
- 0:57SPEAKER_01: Anyone who suggests they have a magic overnight cure for this is simply not operating on evidence-based medicine.
- 1:04SPEAKER_00: Aaron Powell Yeah.
- 1:04SPEAKER_00: That's a very necessary disclaimer.
- 1:06SPEAKER_01: I mean, the clinical data we are analyzing today, it focuses on a fascinating approach to managing the condition and rebalancing the body, not, you know, erasing it from your DNA.
- 1:16SPEAKER_00: Aaron Powell, so let's start by completely dismantling the most common visual misconception.
- 1:21SPEAKER_00: When you hear the word, you picture red scaly plaques.
- 1:25SPEAKER_00: We categorize it visually, you know, we see it on the surface.
- 1:29SPEAKER_01: Because it's visible, sure.
- 1:30SPEAKER_00: But viewing it purely as a dermatological issue is a massive illusion.
- 1:34SPEAKER_00: Those visible plaques are simply the symptom.
- 1:37SPEAKER_00: The fire is burning somewhere else entirely.
- 1:39SPEAKER_01: Aaron Ross Powell The fire is your immune system.
- 1:41SPEAKER_01: I mean, this is fundamentally an autoimmune disease.
- 1:44SPEAKER_01: The skin lesions only happen because an overactive immune system beneath the surface is sending out these faulty signals.
- 1:50SPEAKER_00: Aaron Powell And those signals are driving skin cells to multiply at an unnaturally rapid pace.
- 1:56SPEAKER_01: Aaron Powell Precisely.
- 1:56SPEAKER_01: A normal skin cell turns over in about a month.
- 1:59SPEAKER_01: In this environment, they're multiplying in three to four days.
- 2:01SPEAKER_00: Oh, geez.
- 2:02SPEAKER_01: Yeah.
- 2:02SPEAKER_01: So they pile up on the surface way faster than they can shed, which creates those visible, painful plaques.
- 2:09SPEAKER_01: So focusing solely on the skin is looking at the very end result of a long invisible chain of biological events.
- 2:15SPEAKER_00: Aaron Powell I picture this kind of like, well, like painting over a water stain on your living room ceiling without actually going upstairs to fix the leaky pipe.
- 2:23SPEAKER_01: Aaron Powell That is a perfect way to look at it.
- 2:25SPEAKER_00: You can put as much premium expensive paint on that ceiling as you want.
- 2:29SPEAKER_00: You can slather on topical creams, and it might look perfectly fine for a week.
- 2:33SPEAKER_00: But until you fix the plumbing, that water stain is bleeding right back through.
- 2:38SPEAKER_00: Symptom-focused care misses the underlying driver entirely.
- 2:41SPEAKER_01: Aaron Powell And that plumbing analogy holds up perfectly when you examine what actually triggers a flare.
- 2:47SPEAKER_01: Because the triggers are almost never skin-related.
- 2:49SPEAKER_01: They are systemic events.
- 2:50SPEAKER_00: Like psychological stress.
- 2:52SPEAKER_01: Huge driver.
- 2:52SPEAKER_01: Psychological stress is a massive driver.
- 2:54SPEAKER_01: So as a systemic infection like strep throat, even certain medications, maybe specific blood pressure drugs or mood stabilizers, can throw the system into a flare.
- 3:04SPEAKER_00: Aaron Powell, which proves it's not just a surface issue.
- 3:07SPEAKER_00: I mean, a bacterial throat infection wouldn't cause your elbows or your scalp to break out in plaques three weeks later if it was only about the skin.
- 3:15SPEAKER_01: Aaron Ross Powell Definitely not.
- 3:16SPEAKER_01: And the underlying systemic nature becomes undeniably obvious when you look at the related complications.
- 3:22SPEAKER_01: This is heavily linked to psoriatic arthritis.
- 3:25SPEAKER_00: So we're talking about severe debilitating joint inflammation.
- 3:28SPEAKER_01: A topical steroid cream for your elbow is not going to do anything for the agonizing pain in your knee or your fingers.
- 3:35SPEAKER_01: The systemic immune dysfunction is actively attacking the joints too.
- 3:39SPEAKER_01: The body is essentially turning its defense mechanisms inward.
- 3:43SPEAKER_00: Which I guess fundamentally changes the conversation around how clinical success is actually measured.
- 3:48SPEAKER_00: If you're only treating the skin, you measure success by whether the plaques fade.
- 3:52SPEAKER_01: But when we recognize the systemic immune driver, success is measured by calming the overall immune markers in the blood.
- 4:00SPEAKER_01: Calming that systemic immune response may reduce flare frequency globally, protect the joints, and improve baseline health, rather than just temporarily clearing up a current patch of skin.
- 4:10SPEAKER_00: Okay, so we've established that the pipe is leaking, the immune system is the core issue.
- 4:15SPEAKER_00: How do we actually fix the plumbing?
- 4:18SPEAKER_01: Well, the research outlines a very specific immune tug of war happening inside the body.
- 4:24SPEAKER_01: It really comes down to two specific subtypes of T cells.
- 4:28SPEAKER_00: T cells being essentially the generals of your immune system's defense network.
- 4:33SPEAKER_01: Yes.
- 4:33SPEAKER_01: So on one side of the rope you have TH17 cells.
- 4:36SPEAKER_01: These are your inflammatory cells.
- 4:38SPEAKER_01: They sound the alarm and marshal the troops to fight an infection.
- 4:41SPEAKER_00: And in this condition, TH17 activity tends to run dangerously high.
- 4:45SPEAKER_00: They're pulling the rope relentlessly.
- 4:47SPEAKER_01: Exactly.
- 4:47SPEAKER_01: Then on the other side of the rope, you have regulatory T cells or tregs.
- 4:51SPEAKER_01: Their job is the complete opposite.
- 4:53SPEAKER_01: They're supposed to calm things down, to signal that the threat is gone, and to bring the body back to baseline.
- 4:58SPEAKER_00: Aaron Powell But in this environment, treg activity runs remarkably low.
- 5:02SPEAKER_00: Yes.
- 5:02SPEAKER_00: So the TH17 cells are basically throwing a wild destructive party, and the treg cells are asleep on the couch.
- 5:09SPEAKER_01: Aaron Powell That is a very vivid way to put it, but yes.
- 5:11SPEAKER_01: Now, the standard medical approach for moderate to severe cases has been biologics.
- 5:16SPEAKER_01: These are highly targeted, heavy-duty drugs.
- 5:19SPEAKER_01: They usually aim to block one single inflammatory molecule, like tumor necrosis factor.
- 5:25SPEAKER_00: Hold on, tumor necrosis factor sounds incredibly intense and terrifying.
- 5:29SPEAKER_00: What is that actually doing in my body?
- 5:31SPEAKER_01: I know it sounds much more alarming than it is.
- 5:33SPEAKER_01: Tumor necrosis factor, or TNF, is simply a specific inflammatory protein.
- 5:37SPEAKER_01: It's just one of the chemical signals the body uses to cause inflammation.
- 5:41SPEAKER_00: So biologics are essentially designed to put a massive roadblock in front of that specific signal.
- 5:46SPEAKER_01: Yeah, they bind to it and neutralize it, halting that specific inflammatory cascade.
- 5:51SPEAKER_01: But the therapy outlined by Cyrona cell takes a profoundly different approach using mesenchymal stem cells or MSCs.
- 5:58SPEAKER_00: Instead of just acting as a molecular roadblock for one single protein, the claim is that these stem cells interact with the immune system dynamically.
- 6:06SPEAKER_00: They're trying to shift the broader immune response toward balance.
- 6:09SPEAKER_01: They do this through cellular communication.
- 6:12SPEAKER_01: These stem cells literally secrete tiny chemical messengers, you can think of them as biological text messages, that travel to the immune cells.
- 6:21SPEAKER_00: And according to a recent review of how these cells interact with the immune system, they appear to nudge that T817 and TREG balance back toward regulation.
- 6:30SPEAKER_01: Yes.
- 6:31SPEAKER_01: The chemical signals tell the overactive T817 cells to stand down while simultaneously boosting the activity and reproduction of the calming regulatory T cells.
- 6:41SPEAKER_00: I have to push back here on behalf of the listener, though.
- 6:44SPEAKER_00: If the immune system is fundamentally overactive, does this stem cell therapy just blindly suppress the whole system?
- 6:50SPEAKER_01: Why do you ask that?
- 6:52SPEAKER_00: Because if you're suppressing my entire immune system just to clear up my skin or my joints, you're leaving me highly vulnerable to every passing flu, virus, or random infection.
- 7:02SPEAKER_01: It is a valid concern, but the mechanism is not a blanket suppression.
- 7:05SPEAKER_01: It's a rebalancing act.
- 7:07SPEAKER_01: You can think of blanket suppression like going down to the basement and turning the main electrical breaker off in your house.
- 7:12SPEAKER_00: The lights go out, which stops the electrical fire, but your refrigerator also stops working and all your food spoils.
- 7:18SPEAKER_01: Exactly.
- 7:19SPEAKER_01: Mesenchymal stem cells function more like a smart thermostat.
- 7:22SPEAKER_01: They're constantly sensing the microenvironment of the tissue.
- 7:25SPEAKER_00: So they downregulate the hyperactive inflammatory cells specifically where there is excess inflammation.
- 7:31SPEAKER_01: But they preserve the broader, necessary immune function required to fight off actual pathogens.
- 7:38SPEAKER_00: That brings us to where these smart thermostats actually come from.
- 7:41SPEAKER_00: The Serona Cell Clinic utilizes human umbilical cord tissue, specifically something called Wharton's jelly mesenchymal stem cells.
- 7:50SPEAKER_01: Which sounds like something out of a sci-fi novel.
- 7:52SPEAKER_00: It really does.
- 7:53SPEAKER_00: What is Wharton's jelly, actually?
- 7:54SPEAKER_01: It's the gelatinous connective tissue found within the umbilical cord.
- 7:58SPEAKER_01: Its biological purpose is to insulate and protect the blood vessels inside the cord.
- 8:03SPEAKER_01: And to be clear, these tissues are donated with full maternal consent after a healthy birth.
- 8:08SPEAKER_00: The sourcing of MSCs is a critical variable in regenerative medicine, though.
- 8:12SPEAKER_00: Historically, bone marrow was the original and most heavily studied source.
- 8:16SPEAKER_01: An adipose or fat tissue taken directly from the patient's own body is another common source.
- 8:22SPEAKER_00: So why use the umbilical cord tissue instead of just taking the cells from the patient's own fat?
- 8:27SPEAKER_01: Because each source carries distinct practical and biological trade-offs.
- 8:32SPEAKER_01: The umbilical cord tissue utilized by Cyrona cell is notable because the cells are exceptionally young.
- 8:37SPEAKER_01: They are essentially pristine.
- 8:39SPEAKER_00: Meaning they haven't been exposed to decades of environmental toxins or aging.
- 8:44SPEAKER_01: Or the patient's own underlying autoimmune condition.
- 8:46SPEAKER_01: If a patient has a severe systemic autoimmune disease, their own fat or bone marrow cells have been living in that highly inflammatory dysfunctional environment for years.
- 8:58SPEAKER_00: And that prolonged exposure can compromise the therapeutic efficacy of those autologous cells.
- 9:03SPEAKER_00: So the umbilical cord offers a blank slate.
- 9:05SPEAKER_01: Precisely.
- 9:06SPEAKER_00: Okay, the smart thermostat sounds brilliant in a textbook.
- 9:09SPEAKER_00: Yeah.
- 9:09SPEAKER_00: The idea of pristine young cells sounds great in theory, but theory is cheap in medicine.
- 9:15SPEAKER_00: What happens when you actually infuse these umbilical cells into a human being who has been suffering for a decade?
- 9:20SPEAKER_01: That's where we have to look at the actual clinical data.
- 9:23SPEAKER_01: The sources highlight a pivotal 2022 phase one, two.
- 9:28SPEAKER_01: A human trial testing these exact umbilical cord-derived stem cells.
- 9:33SPEAKER_00: Real human patients here, not just an animal study in the laboratory.
- 9:36SPEAKER_01: Correct.
- 9:37SPEAKER_00: For anyone who doesn't read medical journals on the weekend, what does phase one, two actually mean in terms of what they're testing?
- 9:43SPEAKER_01: Aaron Powell Well, clinical trials follow a strict progression.
- 9:46SPEAKER_01: Phase one is primarily about safety.
- 9:48SPEAKER_01: The researchers are asking, does this harm the patient?
- 9:51SPEAKER_01: Phase two begins to look at efficacy, asking, does this actually help the patient?
- 9:55SPEAKER_00: So a combined phase one to a trial tackles both simultaneously in a small group.
- 10:00SPEAKER_01: Yes.
- 10:01SPEAKER_01: Animal studies in mice had previously shown powerful immune calming effects.
- 10:05SPEAKER_01: But translating results from mice to humans is one of the most notoriously difficult hurdles in all of medical science.
- 10:11SPEAKER_00: So the 2022 trial is significant because it tested this directly in humans, and the safety and preliminary efficacy results were broadly consistent with what the earlier animal studies predicted.
- 10:22SPEAKER_01: What really stands out about this specific group of human patients is their medical history.
- 10:27SPEAKER_01: Several of them had completely stopped responding to standard biologics.
- 10:31SPEAKER_00: They were essentially at the end of the line for conventional approved treatment options.
- 10:36SPEAKER_01: They had tried the heavy-duty drugs and their bodies had rejected them.
- 10:40SPEAKER_01: The trial results showed the intravenous treatment was well tolerated, which satisfied that phase one safety requirement.
- 10:47SPEAKER_00: But beyond safety, some of these treatment-resistant patients showed highly meaningful skin and joint improvement.
- 10:53SPEAKER_01: And the most crucial, unexpected detail from that trial goes far beyond just the skin clearing up.
- 10:59SPEAKER_01: A few patients actually regained their response to the biologic drugs that had previously stopped working for them.
- 11:05SPEAKER_00: Wait, if I take a drug to stop inflammation, my body builds an army to attack the drug, rendering it useless.
- 11:11SPEAKER_00: Then I undergo stem cell therapy, and suddenly that old drug works again.
- 11:15SPEAKER_01: Yes.
- 11:16SPEAKER_00: That feels like a massive biological twist.
- 11:18SPEAKER_01: It really highlights the sheer complexity of the human immune system.
- 11:22SPEAKER_01: Often, a biologic stops working because the patient's immune system is incredibly adaptive.
- 11:28SPEAKER_01: It recognizes the biologic drug, which is often a large, complex protein as a foreign invader, and forms anti-drug antibodies to neutralize it.
- 11:37SPEAKER_01: Yeah.
- 11:37SPEAKER_01: When the mesenchymal stem cells shift the broader immune response toward balance, calming that hyperreactive state, they appear to reset the immunological environment.
- 11:47SPEAKER_00: They calm the system down just enough that the biologic drug can be reintroduced and function properly without being immediately targeted and destroyed.
- 11:55SPEAKER_01: That seems to be the case, yes.
- 11:56SPEAKER_00: I picture this exactly like a factory reset on a struggling, freezing computer.
- 12:00SPEAKER_00: Your computer is bogged down, the software is crashing, nothing is responding to your commands.
- 12:05SPEAKER_01: And the biologic drug is your software in this scenario.
- 12:08SPEAKER_00: Yeah.
- 12:09SPEAKER_00: The stem cells come in, perform a system-level factory reset on the core operating system, clearing out all the corrupted files, and suddenly that old software can boot up and run perfectly again.
- 12:19SPEAKER_01: The factory reset analogy captures the mechanism beautifully.
- 12:24SPEAKER_01: But the trial data, while highly compelling, requires a very grounded perspective.
- 12:29SPEAKER_01: This was a small trial.
- 12:31SPEAKER_00: Researchers still don't fully understand the ideal dose.
- 12:34SPEAKER_01: No, they don't.
- 12:35SPEAKER_01: They don't know the perfect timing or frequency of treatment required to maintain a lasting effect.
- 12:40SPEAKER_01: And perhaps most importantly, they don't yet understand the specific biomarkers that dictate why some patients respond strongly with massive improvement, while others with seemingly identical symptoms see minimal change.
- 12:53SPEAKER_00: That unpredictability leads us directly into how the medical community views these treatments interacting in the real world.
- 13:00SPEAKER_00: The surprise finding of regaining biologic response tells us that stem cells and biologics aren't enemies fighting for the same territory.
- 13:07SPEAKER_01: Definitely not.
- 13:08SPEAKER_01: Biologic drugs remain the absolute backbone of care for moderate to severe cases.
- 13:12SPEAKER_01: They have decades of safety data and massive clinical trials behind them.
- 13:16SPEAKER_00: And they work incredibly well for a huge percentage of patients.
- 13:19SPEAKER_00: So stem cell therapy is considered a complement to standard care.
- 13:23SPEAKER_01: In clinical practice, reputable doctors do not position stem cell therapy as a total replacement for biologics.
- 13:29SPEAKER_01: The evidence points heavily toward a synergistic approach.
- 13:33SPEAKER_00: So the open questions researchers are actively trying to solve right now revolve around how to sequence them for maximum benefit.
- 13:39SPEAKER_01: Right, like should a doctor administer the stem cells before you start a biologic to prep the system and lower the baseline inflammation?
- 13:46SPEAKER_01: Or should they be administered simultaneously during a biologic course to boost the drug's efficacy?
- 13:52SPEAKER_00: Or are they best saved as a rescue therapy for after a biologic course begins to fail, acting specifically as that factory reset we talked about?
- 14:01SPEAKER_01: Measuring success when combining two potent treatments introduces massive complexity into clinical research, too.
- 14:07SPEAKER_01: If a patient's skin clears up and their joint pain vanishes while receiving both MSCs and a biologic, attributing the success to the correct mechanism becomes mathematically and biologically complicated.
- 14:19SPEAKER_00: Plus, you have to wonder if combining both approaches carries any additional long-term risks that require monitoring.
- 14:25SPEAKER_00: These are the complex variables driving the next phase of clinical trials.
- 14:29SPEAKER_01: Taking all of this dense cellular science and bringing it back down to Earth, we have to look at who is actually pursuing this.
- 14:36SPEAKER_01: Who looks at the landscape of available treatments and decides to explore immune modulation through stem cells?
- 14:42SPEAKER_00: Typically, this path is explored by individuals who have exhausted the standard algorithms of care, people with moderate to severe disease whose daily quality of life remains significantly compromised despite trying multiple standard therapies.
- 15:08SPEAKER_00: The patient profile also seems to heavily involve those suffering from psoriatic arthritis alongside their skin symptoms, because they're fighting a brutal two-front war against their own immune system, battling visible skin lesions and invisible joint destruction.
- 15:23SPEAKER_01: So a broader systemic immune rebalancing approach holds significant logical appeal over just slapping on a localized topical treatment.
- 15:30SPEAKER_01: But the practical reality of pursuing this treatment involves substantial, serious logistical planning.
- 15:36SPEAKER_00: Especially since the clinical context we're discussing comes from Cirona Cell, which operates out of Kuala Lumpur.
- 15:41SPEAKER_00: Because they treat a highly international patient base, pursuing this option very often involves traveling across the globe.
- 15:48SPEAKER_01: And medical tourism as an entirely separate, stressful layer of consideration for any patient, especially one dealing with chronic joint pain.
- 15:57SPEAKER_00: You can't just endure a 15-hour flight to Kuala Lumpur, receive an infusion, and assume your medical journey is permanently solved.
- 16:04SPEAKER_00: The clinical guidelines emphasize how critical the follow-up phase is.
- 16:09SPEAKER_01: You must have a rock-solid plan for the months after you return home.
- 16:13SPEAKER_01: Clear, transparent communication with your home dermatologist or rheumatologist is non-negotiable.
- 16:18SPEAKER_00: Your local doctor needs to know exactly what procedure was done, what specific cell source was utilized, what the cell count was, and what the expected clinical trajectory looks like.
- 16:27SPEAKER_01: A reputable regenerative medicine provider will insist on this continuity of care.
- 16:32SPEAKER_01: They should welcome, even encourage, tough questions during the initial consultation phase.
- 16:37SPEAKER_00: If you're sitting in a consultation, whether in Kuala Lumpur or anywhere else, you need to be aggressively proactive.
- 16:44SPEAKER_01: You should be asking how they verify the safety and sterility of their cell source.
- 16:48SPEAKER_01: What are their processing standards?
- 16:50SPEAKER_00: What is the specific scheduled follow-up plan after I fly back to my home country?
- 16:55SPEAKER_00: What happens if a complication arises three weeks later?
- 16:58SPEAKER_01: If a clinic gives vague, dismissive, or evasive answers to those direct logistical questions, that is a massive red flag, regardless of how promising the underlying biology of MSEs looks on paper.
- 17:11SPEAKER_00: And beyond the strict clinical logistics, a comprehensive, successful treatment plan has to acknowledge the patient's lifestyle factors.
- 17:18SPEAKER_00: We discussed earlier that stress is a primary trigger for flares.
- 17:22SPEAKER_01: Sleep quality, dietary choices, and stress management will absolutely not replace medical treatment.
- 17:27SPEAKER_01: You cannot meditate your way out of a severe genetically driven autoimmune disorder.
- 17:32SPEAKER_00: But those factors do meaningfully dictate the chemical environment the immune system is forced to operate in.
- 17:38SPEAKER_00: Managing those lifestyle factors can dictate how often the flares occur and how violently severe they become between your medical treatments.
- 17:46SPEAKER_01: If you are constantly running on four hours of sleep, eating poorly, and living in a state of high psychological stress, you are constantly pulling the T817 side of that immune tug of war.
- 17:57SPEAKER_00: You're working against the therapy.
- 17:59SPEAKER_01: The initial consultation should look at the comprehensive picture, your prior treatment history, the specific extent of your joint involvement, your known lifestyle triggers, and a very realistic, grounded discussion of what stem cell therapy can and cannot promise for your specific, unique biological profile.
- 18:16SPEAKER_00: We have covered incredible ground today.
- 18:18SPEAKER_00: We started by breaking down the persistent illusion that this is merely a skin condition, revealing the systemic, complex immune fire burning beneath the surface.
- 18:27SPEAKER_01: We explored the microscopic tug-of-war between inflammatory T817 cells and calming regulatory T cells.
- 18:33SPEAKER_00: And discussed how umbilical cord mesenchymal stem cells, those pristine cells from the Wharton's jelly, aim to send biological text messages to nudge that balance back toward regulation.
- 18:44SPEAKER_01: We examined the real-world clinical trial data from 2022, showing initial safety and meaningful improvement, as well as a fascinating phenomenon of patients undergoing a biological factory reset and regaining their response to standard biologic drugs.
- 18:59SPEAKER_00: And we established the grounded clinical reality that this is a complementary approach meant to work synergistically alongside the standard backbone of care, requiring careful logistical planning, clear communication with your local doctors, and highly realistic expectations.
- 19:13SPEAKER_01: Which leaves us with a final provocative thought to mull over.
- 19:16SPEAKER_00: Yeah, think about this.
- 19:17SPEAKER_00: The underlying biology we dissected today, that hyperactive immune system getting confused and attacking the body's own tissue, it shares real structural similarities with a whole host of other conditions.
- 19:28SPEAKER_01: If this specific TH17 and Treger rebalancing approach proves consistently effective here, well, could this exact same smart thermostat mechanism eventually change how we treat entirely different autoimmune conditions?
- 19:40SPEAKER_00: Could this be applied to multiple sclerosis, lupus, or rheumatoid arthritis?
- 19:45SPEAKER_00: It is a question that could entirely redefine the future of autoimmune medicine.
- 19:49SPEAKER_00: Thank you for joining us on this deep dive.